MELD-Na score, Acute Physiologic and Chronic Health Evaluation II score, and SOFA score and their association with mortality in critically ill COVID-19 patients with liver injury: A retrospective single-center study

Background: The Acute Physiologic and Chronic Health Evaluation II (APACHE-II), Sequential Organ Failure Assessment (SOFA), and Model for End-Stage Liver Disease modified for Sodium concentration (MELD-Na) scores are validated to predict disease mortality. We studied the prognostic utility of these scoring systems in critically ill coronavirus disease 2019 (COVID-19) patients with liver injury. Methods: This was a retrospective study of 291 confirmed COVID-19 and liver injury patients requiring intensive care unit level of care. These patients required supplemental oxygen requirement with fraction of inspired oxygen >55% and/or the use of vasopressor. MELD-Na, SOFA, and APACHE-II scores were adjusted. Outcomes were mortality and length of stay (LOS). Results: SOFA (odds ratio: 0.78, 95% confidence interval: 0.63–0.98, P < 0.05) was associated with decreased odds for mortality. APACHE-II and MELD-Na were not associated with mortality or LOS. Conclusions: We suggest that the novel nature of COVID-19 necessitates new scoring systems to predict outcomes in critically ill COVID-19 patients with liver injury.

[1]  E. Juárez-Hernández,et al.  Experience in the management of severe COVID-19 patients in an intensive care unit. , 2023, Cirugia y cirujanos.

[2]  R. Facchetti,et al.  COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study , 2021, Gut.

[3]  A. Marcus,et al.  Model of End-Stage Liver Disease (MELD) Score as a Predictor of In-Hospital Mortality in Patients with COVID-19: A Novel Approach to a Classic Scoring System , 2021, Cureus.

[4]  D. Bernstein,et al.  Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study , 2021, Hepatology International.

[5]  P. van Wijngaarden,et al.  No association between COVID-19 related liver injury and the course of disease: a retrospective study , 2020, Scandinavian journal of gastroenterology.

[6]  Matthew D Taylor,et al.  Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm , 2020, Chest.

[7]  A. Çırak,et al.  The impact of charlson comorbidity index on mortality from SARS‐CoV‐2 virus infection and A novel COVID‐19 mortality index: CoLACD , 2020, International journal of clinical practice.

[8]  Lars G. Fritsche,et al.  Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System , 2020, JAMA network open.

[9]  P. Böelle,et al.  Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France , 2020, Journal of clinical medicine.

[10]  A. Farooq,et al.  The Model for End-Stage Liver Disease-Sodium Score at Admission Is Prognostic of Covid-19 Disease Severity , 2020, SN Comprehensive Clinical Medicine.

[11]  S. S. Fatima,et al.  Alcohol consumption and obesity: The hidden scare with COVID-19 severity , 2020, Medical Hypotheses.

[12]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[13]  Kathleen M. Akgün,et al.  Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study , 2020, PLoS medicine.

[14]  M. Ciarleglio,et al.  Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network , 2020, Hepatology.

[15]  Anand Srivastava,et al.  Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. , 2020, JAMA internal medicine.

[16]  C. Aldecoa,et al.  Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study , 2020, Revista Española de Anestesiología y Reanimación (English Edition).

[17]  N. Dowling,et al.  Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center — Boston, Massachusetts, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[18]  Atit Ghoda,et al.  Liver Injury in COVID-19 Infection: A Systematic Review , 2020, Cureus.

[19]  T. Liang,et al.  Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study , 2020, Frontiers in Medicine.

[20]  E. Buscarini,et al.  High rates of 30-day mortality in patients with cirrhosis and COVID-19 , 2020, Journal of Hepatology.

[21]  M. Zervos,et al.  Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit , 2020, JAMA network open.

[22]  J. Schattenberg,et al.  Liver injury in COVID-19: The current evidence , 2020, United European gastroenterology journal.

[23]  Mika Kivimäki,et al.  Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK , 2020, Brain, Behavior, and Immunity.

[24]  Eleanor M. Rees,et al.  COVID-19 length of hospital stay: a systematic review and data synthesis , 2020, BMC Medicine.

[25]  K. Rajendran,et al.  Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review , 2020, Journal of medical virology.

[26]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[27]  P. Olinga,et al.  Potential implications of COVID‐19 in non‐alcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[28]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[29]  H. Okudera,et al.  Characteristics and outcomes of bacteremia among ICU-admitted patients with severe sepsis , 2020, Scientific Reports.

[30]  M. Levy,et al.  The SOFA score—development, utility and challenges of accurate assessment in clinical trials , 2019, Critical Care.

[31]  P. Figueiredo,et al.  The Role of the CLIF-C OF and the 2016 MELD in Prognosis of Cirrhosis with and without Acute-on-Chronic Liver Failure. , 2018, Annals of hepatology.

[32]  Shelly C. Lu,et al.  NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances , 2018, The American Journal of Gastroenterology.

[33]  G. Szabo,et al.  Alcohol’s Effect on Host Defense , 2015, Alcohol research : current reviews.

[34]  J. Ahmad,et al.  Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine , 2013, Hepatic medicine : evidence and research.

[35]  Chris Wakefield,et al.  Cross-validation of a Sequential Organ Failure Assessment score-based model to predict mortality in patients with cancer admitted to the intensive care unit. , 2012, Journal of critical care.

[36]  R. Cavallazzi,et al.  Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis. , 2012, Journal of critical care.

[37]  F. Lee,et al.  Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  W. Serednicki,et al.  Validation of APACHE II and SAPS II scales at the intensive care unit along with assessment of SOFA scale at the admission as an isolated risk of death predictor. , 2019, Anaesthesiology intensive therapy.

[39]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.